ACH-2684 has several unique characteristics that make it of high interest to Achillion:
- The compound retains potent activity against all genotypes (1-6)
- The compound effectively suppresses a broad range of natural variants of the hepatitis C virus
- The compound retains activity against commonly observed protease inhibitor-induced mutations
- The compound can be effectively used in combination with other HCV inhibitors, and is synergistic with NS5B nucleoside polymerase inhibitors
- The compound has good pharmacokinetic and safety profiles in pre-clinical studies
In the wild type replicon assay, ACH-2684 compares quite favorably to other protease inhibitors.
In pre-clinical in vivo studies, the following dose-curves were observed:
